Want to see MLTX full AI Analyst Report?
MoonLake Immunotherapeutics (MLTX) Ratios
677 Followers
MoonLake Immunotherapeutics Ratios
MLTX's free cash flow for Q3 2026 was $-63.40M. For the 2026 fiscal year, MLTX's free cash flow was increased by $0.00 and operating cash flow was $-63.40M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 9.27 | 21.11 | 51.59 | 9.98 | 0.46 |
| Quick Ratio | 9.27 | 21.11 | 51.59 | 9.98 | 0.46 |
| Cash Ratio | 7.36 | 8.03 | 45.27 | 5.15 | 0.38 |
| Solvency Ratio | -1.87 | -4.79 | -2.73 | -6.17 | -2.52 |
| Operating Cash Flow Ratio | -4.31 | -5.19 | -4.29 | -7.29 | -1.67 |
| Short-Term Operating Cash Flow Coverage | -158.84 | 0.00 | 0.00 | 0.00 | -2.35 |
| Net Current Asset Value | $ 301.74M | $ 449.75M | $ 501.12M | $ 68.43M | $ -11.69M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.18 | 0.01 | 0.01 | 0.00 | 1.55 |
| Debt-to-Equity Ratio | 0.25 | 0.01 | 0.01 | 0.01 | -1.29 |
| Debt-to-Capital Ratio | 0.20 | 0.01 | 0.01 | 0.01 | 4.47 |
| Long-Term Debt-to-Capital Ratio | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.39 | 1.07 | 1.06 | 1.57 | -0.83 |
| Debt Service Coverage Ratio | -25.99 | 0.00 | 0.00 | 0.00 | -3.58 |
| Interest Coverage Ratio | -33.78 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.09 | 0.00 | 0.00 | 0.00 | 0.04 |
| Interest Debt Per Share | 1.29 | 0.05 | 0.08 | 0.01 | 0.41 |
| Net Debt to EBITDA | 1.18 | 1.49 | 8.32 | 0.60 | -0.13 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 98.96% | 98.32% | 81.86% | 77.51% | 100.01% |
| EBT Per EBIT | 93.82% | 84.54% | 81.27% | 99.09% | 100.12% |
| Return on Assets (ROA) | -53.56% | -24.89% | -6.84% | -65.03% | -554.03% |
| Return on Equity (ROE) | -74.66% | -26.62% | -7.26% | -102.20% | 460.66% |
| Return on Capital Employed (ROCE) | -64.61% | -31.42% | -10.48% | -94.05% | 469.76% |
| Return on Invested Capital (ROIC) | -64.40% | -31.32% | -10.45% | -93.84% | -1490.38% |
| Return on Tangible Assets | -53.56% | -24.89% | -6.84% | -65.03% | -554.03% |
| Earnings Yield | -26.75% | -3.49% | -1.21% | -16.21% | -14.69% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | -90539.24 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 90539.24 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -3.04 | -1.85 | -0.87 | -1.90 | -0.95 |
| Free Cash Flow Per Share | -3.04 | -1.86 | -0.88 | -1.90 | -0.95 |
| Dividend Paid and CapEx Coverage Ratio | -5600.20 | -224.41 | -150.29 | -3491.19 | -693.71 |
| Capital Expenditure Coverage Ratio | -5600.20 | -224.41 | -150.29 | -3491.19 | -693.71 |
| Operating Cash Flow Coverage Ratio | -2.59 | -41.20 | -11.57 | -197.80 | -2.35 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -23.07% | -3.44% | -1.45% | -18.14% | -9.65% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -3.73 | -28.65 | -82.39 | -6.17 | -6.81 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 2.79 | 7.62 | 5.98 | 6.30 | -31.36 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -4.33 | -29.07 | -68.89 | -5.51 | -10.37 |
| Price-to-Operating Cash Flow Ratio | -4.33 | -29.20 | -69.35 | -5.52 | -10.38 |
| Price-to-Earnings Growth (PEG) Ratio | -0.04 | -0.18 | 1.23 | -0.12 | -0.00 |
| Enterprise Value Multiple | -2.69 | -26.99 | -46.86 | -4.15 | -6.94 |
| Enterprise Value | 590.83M | 3.23B | 2.52B | 269.07M | 372.16M |
| EV to EBITDA | -2.69 | -26.99 | -46.86 | -4.15 | -6.94 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -3.01 | -27.55 | -58.50 | -4.81 | -10.56 |
| EV to Operating Cash Flow | -3.01 | -27.68 | -58.89 | -4.81 | -10.58 |
| Tangible Book Value Per Share | 4.72 | 7.21 | 10.45 | 2.34 | -0.32 |
| Shareholders’ Equity Per Share | 4.72 | 7.11 | 10.09 | 1.67 | -0.32 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -3.53 | -1.89 | -0.73 | -1.70 | -1.45 |
| Tax Burden | 0.99 | 0.98 | 0.82 | 0.78 | 1.00 |
| Interest Burden | 1.03 | 1.00 | 0.81 | 0.99 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.86 | 0.96 | 0.97 | 1.12 | 0.66 |
Currency in USD
